Document Detail

Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
MedLine Citation:
PMID:  22334369     Owner:  NLM     Status:  MEDLINE    
CONCLUSION: Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone.
Stephen A Harrison; Fayez M Hamzeh; Jian Han; Prashant K Pandya; Muhammed Y Sheikh; John M Vierling
Related Documents :
6290109 - Recovery of hypothalamo-pituitary-adrenal function in asthmatics whose oral steroids ha...
20609969 - Once weekly exenatide compared with insulin glargine titrated to target in patients wit...
12166599 - Hypoglycaemic valleys: an under-recognised problem in type 2 diabetes?
1050019 - Stomach motility in insulin-treated sheep.
15244099 - Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection ...
1222999 - Acid inhibiton in insulin test- a preliminary report.
24353559 - Adherence of healthcare professionals to american diabetes association 2004 guidelines ...
9332269 - Occult extraadrenal pheochromocytoma treated as diabetes mellitus.
19146569 - Comparing cost-of-illness estimates from alternative approaches: an application to diab...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2012-06-11
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  56     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-26     Completed Date:  2012-10-11     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  464-73     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 American Association for the Study of Liver Diseases.
Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / administration & dosage,  adverse effects
Diabetes Mellitus, Type 2 / drug therapy,  epidemiology
Drug Therapy, Combination
Follow-Up Studies
Hepacivirus / drug effects*,  genetics
Hepatitis C, Chronic / drug therapy*,  epidemiology,  virology
Hypoglycemic Agents / administration & dosage,  adverse effects
Insulin Resistance / physiology*
Interferon-alpha / administration & dosage*,  adverse effects
Liver Cirrhosis / epidemiology,  virology
Middle Aged
Polyethylene Glycols / administration & dosage*,  adverse effects
Recombinant Proteins / administration & dosage,  adverse effects
Ribavirin / administration & dosage*,  adverse effects
Risk Factors
Thiazolidinediones / administration & dosage*,  adverse effects
Treatment Outcome
Reg. No./Substance:
0/Antiviral Agents; 0/Hypoglycemic Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/Thiazolidinediones; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; X4OV71U42S/pioglitazone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  ZnO Coaxial Nanorod Homojunction UV Light-Emitting Diodes Prepared by Aqueous Solution Method.
Next Document:  Next-generation genetic testing for retinitis pigmentosa.